FDA Grants Priority Review for Pfizer and Astellas' Padcev with Keytruda for Bladder Cancer
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 20 2026
0mins
Source: seekingalpha
- FDA Priority Review: Pfizer and Astellas announced that the FDA has granted priority review for their marketing application of Padcev in combination with Merck's Keytruda, marking a significant advancement in bladder cancer treatment.
- Indication Expansion: The application aims to expand the use of Padcev with Keytruda to all muscle-invasive bladder cancer patients, not just those ineligible for cisplatin chemotherapy, which is expected to significantly broaden the potential market.
- Clinical Trial Success: This application is based on data from the Phase 3 EV-304 trial, which successfully met its primary endpoint of event-free survival, providing strong support for FDA approval of the therapy.
- Target Action Date: The FDA has set August 17, 2026, as the target action date for the supplemental Biologics License Application, and if approved, it will offer new treatment options for patients, further solidifying Pfizer and Astellas' market position in oncology.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PFE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PFE
Wall Street analysts forecast PFE stock price to rise
16 Analyst Rating
5 Buy
11 Hold
0 Sell
Moderate Buy
Current: 25.620
Low
24.00
Averages
28.56
High
35.00
Current: 25.620
Low
24.00
Averages
28.56
High
35.00
About PFE
Pfizer Inc. is a research-based, global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment includes the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its oncology products include Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak and Talzenna. Its primary care products include Eliquis, Nurtec ODT/Vydura, Zavzpret, the Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix, Trumenba, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Abrilada, Cibinqo, Litfulo, Eucrisa, Velsipity, the Vyndaqel family, Genotropin, and others. Its PF-08653944 is an ultra-long-acting fully biased GLP-1 receptor agonist.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
FDA Approves Expanded Use of HYMPAVZI for Hemophilia Treatment in Adolescents
- Expanded Indication: The FDA has approved HYMPAVZI for use in patients aged 12 and older with hemophilia A or B and pediatric patients aged 6 to 11, marking the first availability of a non-factor treatment for this age group, addressing a significant medical need.
- Significant Efficacy: Results from the Phase 3 BASIS trial demonstrated that HYMPAVZI reduced the annualized bleeding rate (ABR) by 93% in adults and adolescents, showcasing its superior efficacy in managing bleeding episodes compared to traditional therapies.
- Simplified Administration: HYMPAVZI offers a once-weekly subcutaneous administration that eliminates the need for routine treatment-related lab monitoring, significantly reducing the treatment burden for patients and caregivers, thereby enhancing adherence to therapy.
- Global Market Potential: With regulatory approvals in over 40 countries, Pfizer is committed to pursuing further global regulatory approvals for HYMPAVZI, aiming to expand its market presence and meet the treatment needs of hemophilia patients worldwide.
See More
Activist Investor Pushes for Sale of Ashland Inc to Boost Share Price
- Increased Shareholder Pressure: Activist investor Ancora Alternatives has built a significant stake in Ashland Inc (ASH.N) and argues that a sale could boost the share price by at least 30%, demonstrating strong confidence in the company's future value.
- Background of Stock Decline: Since hitting a high in December 2022, Ashland's stock price has tumbled roughly 50%, now trading near $57.50, reflecting investor punishment for disappointing performance, with a market value of only $2.7 billion.
- Acquisition Potential Analysis: Ancora forecasts that a sale could push the stock price to at least $76, marking a 31% increase, indicating that the company's intrinsic value remains underappreciated amid current trading discounts and growth challenges.
- Possibility of Management Changes: Ancora is prepared to launch a proxy fight during the upcoming shareholder nomination window if constructive dialogue with management does not yield a resolution, aiming to add fresh leadership to the board to ensure proper fiduciary oversight.
See More
New Advances in Cancer Treatment in Biotechnology
- Breakthrough in Neuro-Oncology: NeOnc Technologies is focused on developing innovative therapies for malignant brain tumors, aiming to overcome the blood-brain barrier, which is expected to significantly enhance treatment efficacy and meet the urgent market demand for effective brain cancer therapies.
- Critical Clinical Milestone: Upcoming Phase 2 clinical trials for NeOnc are viewed as a pivotal inflection point; if positive efficacy signals are observed in aggressive brain cancers, it could attract increased investor interest and facilitate strategic partnerships, driving the company's growth.
- GSK Acquires Nuvalent: GSK's acquisition of Nuvalent for approximately $10.6 billion strengthens its oncology portfolio, indicating intensified competition among major pharmaceutical companies to secure innovative cancer therapies, which is expected to drive long-term growth.
- Future of Precision Medicine: As advancements in precision medicine and biotechnology continue, treatment options targeting specific cancer-driving mutations will become industry focal points, with innovations from companies like NeOnc and Nuvalent potentially leading the next wave of oncology treatment.
See More
Zai Lab's Tivdak Approved in China for Cervical Cancer Treatment
- Drug Approval: Zai Lab's Tivdak has received approval from China's National Medical Products Administration as a treatment for late-line cervical cancer patients, marking a significant advancement for the company in the biopharmaceutical sector.
- Clinical Trial Support: The approval is supported by data from the global Phase 3 trial innovaTV 301, which indicated that Tivdak significantly improved overall survival compared to chemotherapy in the targeted patient population, particularly among Chinese patients.
- Market Potential: With approximately 150,000 cervical cancer diagnoses annually in China, and limited treatment options for recurrent or metastatic cases, the launch of Tivdak offers new hope for these patients and addresses a critical market need.
- Strategic Partnership: In 2022, Zai Lab secured exclusive rights to develop and commercialize Tivdak in mainland China, Hong Kong, Macau, and Taiwan, further solidifying its strategic partnership with Pfizer and Genmab, thereby enhancing its competitive position in the biopharmaceutical market.
See More
Space Pharma Market Thrives Amidst Mega-IPO Frenzy
- Market Potential: Morgan Stanley predicts that the space economy could exceed $1 trillion by 2040, with the pharmaceutical sector likely to experience the most immediate disruption, prompting a growing number of companies to explore drug development in low Earth orbit.
- Technological Breakthroughs: Redwire's SpaceMD has successfully flown 54 PIL-BOX units and tested 37 drug compounds, leveraging the zero-gravity environment to produce more uniform drug crystals, thereby enhancing drug absorbability and stability.
- Strengthened Partnerships: SpaceMD's collaboration with pharmaceutical giants like Eli Lilly and Bristol Myers Squibb showcases the potential of new crystal forms, driving the development of new drug candidates and highlighting the commercial viability of space pharmaceuticals.
- Future Directions: As the International Space Station approaches retirement, SpaceMD is establishing relationships with commercial low Earth orbit destination providers, aiming for increased flight frequency and the development of fixed infrastructure to support the long-term growth of space pharmaceuticals.
See More
Commercialization Prospects of Space Pharmaceuticals
- Space Drug Development: SpaceMD CEO John Vellinger stated that utilizing the space environment can resolve hundreds of drug compounds sidelined annually due to crystallization errors, which is expected to have an immediate impact on the pharmaceutical industry.
- Technological Innovation: SpaceMD has successfully flown 54 PIL-BOX units and tested 37 drug compounds, demonstrating that crystals grown in zero gravity are more uniform and stable, thereby enhancing drug usability and absorption rates.
- Market Potential: Morgan Stanley predicts that the space economy will exceed $1 trillion by 2040, with the pharmaceutical sector being one of the first beneficiaries, as commercial opportunities continue to expand with the establishment of necessary infrastructure.
- International Collaboration: The UK Space Agency is investing in projects exploring the feasibility of manufacturing drugs in space, with BioOrbit developing scalable systems for crystallizing and manufacturing complex biologics, driving innovation in the drug market.
See More
FDA Approves Expanded Use of HYMPAVZI for Hemophilia Treatment in Adolescents
- Expanded Indication: The FDA has approved HYMPAVZI for use in patients aged 12 and older with hemophilia A or B and pediatric patients aged 6 to 11, marking the first availability of a non-factor treatment for this age group, addressing a significant medical need.
- Significant Efficacy: Results from the Phase 3 BASIS trial demonstrated that HYMPAVZI reduced the annualized bleeding rate (ABR) by 93% in adults and adolescents, showcasing its superior efficacy in managing bleeding episodes compared to traditional therapies.
- Simplified Administration: HYMPAVZI offers a once-weekly subcutaneous administration that eliminates the need for routine treatment-related lab monitoring, significantly reducing the treatment burden for patients and caregivers, thereby enhancing adherence to therapy.
- Global Market Potential: With regulatory approvals in over 40 countries, Pfizer is committed to pursuing further global regulatory approvals for HYMPAVZI, aiming to expand its market presence and meet the treatment needs of hemophilia patients worldwide.
See More
Activist Investor Pushes for Sale of Ashland Inc to Boost Share Price
- Increased Shareholder Pressure: Activist investor Ancora Alternatives has built a significant stake in Ashland Inc (ASH.N) and argues that a sale could boost the share price by at least 30%, demonstrating strong confidence in the company's future value.
- Background of Stock Decline: Since hitting a high in December 2022, Ashland's stock price has tumbled roughly 50%, now trading near $57.50, reflecting investor punishment for disappointing performance, with a market value of only $2.7 billion.
- Acquisition Potential Analysis: Ancora forecasts that a sale could push the stock price to at least $76, marking a 31% increase, indicating that the company's intrinsic value remains underappreciated amid current trading discounts and growth challenges.
- Possibility of Management Changes: Ancora is prepared to launch a proxy fight during the upcoming shareholder nomination window if constructive dialogue with management does not yield a resolution, aiming to add fresh leadership to the board to ensure proper fiduciary oversight.
See More
New Advances in Cancer Treatment in Biotechnology
- Breakthrough in Neuro-Oncology: NeOnc Technologies is focused on developing innovative therapies for malignant brain tumors, aiming to overcome the blood-brain barrier, which is expected to significantly enhance treatment efficacy and meet the urgent market demand for effective brain cancer therapies.
- Critical Clinical Milestone: Upcoming Phase 2 clinical trials for NeOnc are viewed as a pivotal inflection point; if positive efficacy signals are observed in aggressive brain cancers, it could attract increased investor interest and facilitate strategic partnerships, driving the company's growth.
- GSK Acquires Nuvalent: GSK's acquisition of Nuvalent for approximately $10.6 billion strengthens its oncology portfolio, indicating intensified competition among major pharmaceutical companies to secure innovative cancer therapies, which is expected to drive long-term growth.
- Future of Precision Medicine: As advancements in precision medicine and biotechnology continue, treatment options targeting specific cancer-driving mutations will become industry focal points, with innovations from companies like NeOnc and Nuvalent potentially leading the next wave of oncology treatment.
See More
Zai Lab's Tivdak Approved in China for Cervical Cancer Treatment
- Drug Approval: Zai Lab's Tivdak has received approval from China's National Medical Products Administration as a treatment for late-line cervical cancer patients, marking a significant advancement for the company in the biopharmaceutical sector.
- Clinical Trial Support: The approval is supported by data from the global Phase 3 trial innovaTV 301, which indicated that Tivdak significantly improved overall survival compared to chemotherapy in the targeted patient population, particularly among Chinese patients.
- Market Potential: With approximately 150,000 cervical cancer diagnoses annually in China, and limited treatment options for recurrent or metastatic cases, the launch of Tivdak offers new hope for these patients and addresses a critical market need.
- Strategic Partnership: In 2022, Zai Lab secured exclusive rights to develop and commercialize Tivdak in mainland China, Hong Kong, Macau, and Taiwan, further solidifying its strategic partnership with Pfizer and Genmab, thereby enhancing its competitive position in the biopharmaceutical market.
See More
Space Pharma Market Thrives Amidst Mega-IPO Frenzy
- Market Potential: Morgan Stanley predicts that the space economy could exceed $1 trillion by 2040, with the pharmaceutical sector likely to experience the most immediate disruption, prompting a growing number of companies to explore drug development in low Earth orbit.
- Technological Breakthroughs: Redwire's SpaceMD has successfully flown 54 PIL-BOX units and tested 37 drug compounds, leveraging the zero-gravity environment to produce more uniform drug crystals, thereby enhancing drug absorbability and stability.
- Strengthened Partnerships: SpaceMD's collaboration with pharmaceutical giants like Eli Lilly and Bristol Myers Squibb showcases the potential of new crystal forms, driving the development of new drug candidates and highlighting the commercial viability of space pharmaceuticals.
- Future Directions: As the International Space Station approaches retirement, SpaceMD is establishing relationships with commercial low Earth orbit destination providers, aiming for increased flight frequency and the development of fixed infrastructure to support the long-term growth of space pharmaceuticals.
See More
Commercialization Prospects of Space Pharmaceuticals
- Space Drug Development: SpaceMD CEO John Vellinger stated that utilizing the space environment can resolve hundreds of drug compounds sidelined annually due to crystallization errors, which is expected to have an immediate impact on the pharmaceutical industry.
- Technological Innovation: SpaceMD has successfully flown 54 PIL-BOX units and tested 37 drug compounds, demonstrating that crystals grown in zero gravity are more uniform and stable, thereby enhancing drug usability and absorption rates.
- Market Potential: Morgan Stanley predicts that the space economy will exceed $1 trillion by 2040, with the pharmaceutical sector being one of the first beneficiaries, as commercial opportunities continue to expand with the establishment of necessary infrastructure.
- International Collaboration: The UK Space Agency is investing in projects exploring the feasibility of manufacturing drugs in space, with BioOrbit developing scalable systems for crystallizing and manufacturing complex biologics, driving innovation in the drug market.
See More
